# Bio Key International Inc: overview BKYI · Nasdaq · CIK 1019034 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bkyi.md) · [Financials](/companies/bkyi/financials.md) · [Filings](/companies/bkyi/filings.md) · [Insiders](/companies/bkyi/insiders.md) Latest reported revenue: [$1.9m](/filings/0001437749-26-027723.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-027723). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,145](/filings/0001437749-25-035227.md) | [1,462 d](/filings/0001437749-26-020446.md) | [1,607](/filings/0001437749-26-021335.md) | [1,697](/filings/0001437749-26-027723.md) | [1,550](/filings/0001437749-25-035227.md) | [1,084 d](/filings/0001437749-26-020446.md) | [2,146](/filings/0001437749-26-021335.md) | [1,920](/filings/0001437749-26-027723.md) | | Gross margin | % | [78.3%](/filings/0001437749-25-035227.md) | [82.1% d](/filings/0001437749-26-020446.md) | [82.6%](/filings/0001437749-26-021335.md) | [72.6%](/filings/0001437749-26-027723.md) | [76.9%](/filings/0001437749-25-035227.md) | [75.0% d](/filings/0001437749-26-020446.md) | [82.5%](/filings/0001437749-26-021335.md) | [87.2%](/filings/0001437749-26-027723.md) | | Operating margin | % | [(27.1%)](/filings/0001437749-25-035227.md) | [(86.7%) d](/filings/0001437749-26-020446.md) | [(39.9%)](/filings/0001437749-26-021335.md) | [(63.9%)](/filings/0001437749-26-027723.md) | [(57.6%)](/filings/0001437749-25-035227.md) | [(388.5%) d](/filings/0001437749-26-020446.md) | [(7.4%)](/filings/0001437749-26-021335.md) | [(27.6%)](/filings/0001437749-26-027723.md) | | Net margin | % | [(34.5%)](/filings/0001437749-25-035227.md) | [(94.7%) d](/filings/0001437749-26-020446.md) | [(45.8%)](/filings/0001437749-26-027723.md) | [(68.8%)](/filings/0001437749-26-027723.md) | [(62.3%)](/filings/0001437749-25-035227.md) | [(395.8%) d](/filings/0001437749-26-020446.md) | [(9.6%)](/filings/0001437749-26-027723.md) | [(30.0%)](/filings/0001437749-26-027723.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(1,297) d](/filings/0001437749-25-035227.md) | [(525) d](/filings/0001437749-26-020446.md) | [(840)](/filings/0001437749-26-021335.md) | [(881) d](/filings/0001437749-26-027723.md) | [(1,124) d](/filings/0001437749-25-035227.md) | [(1,835) d](/filings/0001437749-26-020446.md) | [(358)](/filings/0001437749-26-021335.md) | [(846) d](/filings/0001437749-26-027723.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [5,114](/filings/0001437749-23-016374.md) | [7,020](/filings/0001437749-24-019357.md) | [7,755](/filings/0001437749-25-012824.md) | [6,930](/filings/0001437749-26-020446.md) | [5,938](/filings/0001437749-26-020446.md) | | Gross margin | % | [67.3%](/filings/0001437749-23-016374.md) | [65.2%](/filings/0001437749-24-019357.md) | [18.5%](/filings/0001437749-25-012824.md) | [81.4%](/filings/0001437749-26-020446.md) | [76.9%](/filings/0001437749-26-020446.md) | | Operating margin | % | [(96.6%)](/filings/0001437749-23-016374.md) | [(141.4%)](/filings/0001437749-24-019357.md) | [(113.8%)](/filings/0001437749-25-012824.md) | [(57.9%)](/filings/0001437749-26-020446.md) | [(115.0%)](/filings/0001437749-26-020446.md) | | Net margin | % | [(99.0%)](/filings/0001437749-23-016374.md) | [(169.7%)](/filings/0001437749-24-019357.md) | [(109.9%)](/filings/0001437749-25-012824.md) | [(62.1%)](/filings/0001437749-26-020446.md) | [(120.6%)](/filings/0001437749-26-020446.md) | | Diluted EPS | $ per share | [(0.65)](/filings/0001437749-22-007930.md) | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(9,020)](/filings/0001437749-23-016374.md) | [(6,311)](/filings/0001437749-24-019357.md) | [(3,794)](/filings/0001437749-25-012824.md) | [(2,927)](/filings/0001437749-26-020446.md) | [(4,681)](/filings/0001437749-26-020446.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bkyi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) None of the funds in coverage reports a position in its latest 13F. ## Recent filings [All 935 filings](/companies/bkyi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 17:06 ET | [8-K](/filings/0001437749-26-034242.md) | 5.07 Shareholder vote results | 0001437749-26-034242 | | 2026-10-30 | 17:02 ET | [S-1/A](/filings/0001437749-26-034238.md) | Registration statement, amended | 0001437749-26-034238 | | 2026-10-09 | 17:00 ET | [S-1](/filings/0001437749-26-032451.md) | Registration statement | 0001437749-26-032451 | | 2026-10-06 | 16:48 ET | [8-K](/filings/0001437749-26-032237.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001437749-26-032237 | | 2026-10-02 | 17:02 ET | [8-K](/filings/0001437749-26-031903.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-031903 | | 2026-09-08 | 17:04 ET | [8-K](/filings/0001437749-26-029849.md) | 8.01 Other events | 0001437749-26-029849 | | 2026-08-14 | 08:01 ET | [8-K](/filings/0001437749-26-027829.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027829 | | 2026-08-13 | 16:56 ET | [8-K](/filings/0001437749-26-027730.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-027730 | | 2026-08-13 | 16:49 ET | [10-Q](/filings/0001437749-26-027723.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027723 | | 2026-07-24 | 16:15 ET | [DEF 14A](/filings/0001437749-26-024414.md) | Proxy statement, period 2026-09-03 | 0001437749-26-024414 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-020446.md), filed Jun 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9b15c64e-b932-491a-8d82-e82bc30a968f) ## About the filer - CIK: 1019034 - Tickers: BKYI - Exchange: Nasdaq - SIC code: 7372 Services-Prepackaged Software - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:15 ET. No prices; not investment advice.